retatrutide phase 2 obesity nejm 2023 jastreboff SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Triple–Hormone-Receptor Agonist Retatrutide for Obesity
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12






:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)


















